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Discovery of cahuitamycins as bioﬁlm inhibitors
derived from a convergent biosynthetic pathway
Sung Ryeol Park1,*, Ashootosh Tripathi1,*, Jianfeng Wu2, Pamela J. Schultz1, Isaiah Yim1,w, Thomas J. McQuade1,
Fengan Yu1, Carl-Johan Arevang1,w, Abraham Y. Mensah1,w, Giselle Tamayo-Castillo3,4, Chuanwu Xi2
& David H. Sherman1,5,6,7
Pathogenic microorganisms often have the ability to attach to a surface, building a complex
matrix where they colonize to form a bioﬁlm. This cellular superstructure can display
increased resistance to antibiotics and cause serious, persistent health problems in humans.
Here we describe a high-throughput in vitro screen to identify inhibitors of Acinetobacter
baumannii bioﬁlms using a library of natural product extracts derived from marine microbes.
Analysis of extracts derived from Streptomyces gandocaensis results in the discovery of three
peptidic metabolites (cahuitamycins A–C), with cahuitamycin C being the most effective
inhibitor (IC50¼ 14.5mM). Biosynthesis of cahuitamycin C proceeds via a convergent bio-
synthetic pathway, with one of the steps apparently being catalysed by an unlinked gene
encoding a 6-methylsalicylate synthase. Efforts to assess starter unit diversiﬁcation through
selective mutasynthesis lead to production of unnatural analogues cahuitamycins D and E of
increased potency (IC50¼8.4 and 10.5mM).
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W
idespread antibiotic resistance is currently posing a
grave health burden through a multitude of serious
infections1. The rise in bacterial adaptation can be
directly correlated to the paucity of novel classes of antimicrobial
agents2. In the past few decades, synthetic tailoring has been the
primary strategy for enhancing established core scaffolds through
analogue generation. Although this approach has been fruitful, no
major classes of new antibiotics were introduced between 1962
and 2000 (ref. 3). Therefore, to restore robust access to effective
therapeutic agents, it is imperative that we engage in aggressive
efforts to discover novel chemical entities with unique microbial
targets2,4.
Acinetobacter baumannii belongs to the ESKAPE group of
major nosocomial opportunistic resistance pathogens (Entero-
coccus faecalis, Staphylococcus aureus, Klebsiella pneumoniae, A.
baumannii, Pseudomonas aeruginosa and Enterobacter sp.),
which can spread epidemically among patients causing ventila-
tor-associated pneumonia and bacteremia, with mortality rates as
high as 60%, representing a paradigm of pathogenesis, transmis-
sion and resistance5. Numerous reports have also shown startling
emergence of multidrug resistant A. baumannii in hospitals, and
also identiﬁcation of pan-drug-resistant strains at some
locations5,6. A. baumannii strains possess both intrinsic
resistance to antibiotics and a facile ability to acquire genes
encoding resistance determinants. In addition, antibiotic
resistance of this pathogenic microbe appears to be mediated by
their propensity to form bioﬁlms with a highly structured
extracellular polymeric matrix, and includes the ability to
colonize medical devices. When attached, bacterial cells that
comprise the bioﬁlm possess 10–1,000-fold lower susceptibility
towards antimicrobial agents compared with planktonic forms7.
Moreover, despite the central role that bacterial bioﬁlms play
during infection, there are currently no drugs speciﬁcally
targeting bioﬁlms in clinical trials to date8,9. Therefore, a
precision medicine is urgently required for vulnerable patients
to avoid potential life-threatening infections. Recently, developing
bioﬁlm inhibitors has become a priority compared with bioﬁlm
disruption due to the advantage provided by preventing
subsequent dispersion of cells that may have acquired drug
resistance10–12. Although bioﬁlm control by drug targeting has
become a high priority objective7,13, marine microbes as a source
of novel chemical entities remain relatively underexplored14,15.
In our continuing effort to identify new structural classes of
antibiotics4, we employed static- and ﬂow-based high-throughput
screening (HTS) assays to survey our natural product extract
(NPE) library in the search for new inhibitors of bioﬁlm
formation16. Here we describe the discovery of three novel
secondary metabolites, whose stable production and full
structural identiﬁcation required ribosome engineering, and was
facilitated by biosynthetic gene cluster characterization. In
addition, we show that the cahuitamycins are derived from two
independent starter unit pathways, one of which is genetically
unlinked to the core cluster. The convergent pathway enabled us
to perform directed pathway engineering to generate a more
potent molecule, selectively. Furthermore, mutasynthetic efforts
on the ribosomally modulated strain generated two additional
novel compounds with enhanced activity against bioﬁlm
formation.
Results and Discussion
HTS for bioﬁlm inhibitors against A. baumannii. In an effort to
discover new antibiotics to combat hospital-associated infections
in patients, we proceeded to screen our marine microbial-derived
NPE library to identify bioﬁlm inhibitors of A. baumannii. Nat-
ural products account for the majority of currently marketed
drugs17, and the marine microbiome represents a potential new
source of unique chemical entities18. We adapted a crystal-violet-
based high-throughput assay19 that was queried against a library
of 9,831 marine microbial-derived NPEs to identify the extracts
inhibiting bioﬁlm formation as the primary screen. The active
extracts were further prioritized by setting the inhibition
threshold to 50% followed by a dose–response assay, yielding
31 active NPEs (Supplementary Figs 1–2). A second round of
microbial biological activity analysis was conducted on the top
nine most potent extracts (Supplementary Fig. 2). This study
revealed the extract from Streptomyces gandocaensis to be of
particular interest due to its ability to inhibit bioﬁlm formation,
but showing a limited effect on A. baumannii growth
(Supplementary Figs 1–3).
Ribosome engineering of S. gandocaensis. Following initial
identiﬁcation of the active principles, regrowth of the wild-type
S. gandocaensis over several months showed complete loss of
production of the active bioﬁlm inhibitor molecules. Therefore,
we decided to immediately pursue a ribosome engineering
approach to restore and improve production of the active meta-
bolites. This approach has been employed for activation of
secondary metabolite production in Streptomyces spp.20, and can
result in signiﬁcantly enhanced yields by inducing point
mutations in ribosomal protein-encoding genes (for example,
rpsL). Several rounds of mutagenesis based on a streptomycin
resistance phenotype resulted in an improved strain DHS287
of S. gandocaensis (Supplementary Fig. 4; Supplementary
Table 7), a fourth-generation mutant with restored stable
production that generates several-fold increased quantities of
active molecules compared with initial wild-type levels. Genetic
analysis revealed that the streptomycin-induced ribosome
engineering introduced a point mutation in the rpsL gene,
which encodes the ribosomal protein S12, in the engineered strain
(Supplementary Fig. 5; Supplementary Table 3). Previous studies
have shown that mutations in the S12 gene render cells
potentially more active for polypeptide synthesis under typical
starvation conditions during the late growth phase20. This effort
appears to be the ﬁrst reported instance where complete loss of an
active, but structurally uncharacterized natural product has been
recovered using the ribosome engineering approach.
Isolation and structure elucidation of cahuitamycins A–C.
Bioassay guided C18 column fractionation followed by high-
performance liquid chromatography (HPLC) puriﬁcation of
organic extracts obtained from the ribosome-engineered S. gan-
docaensis DHS287 yielded three new secondary metabolites,
cahuitamycins A–C (1–3; Fig. 1). Cahuitamycin A (1), the major
metabolite, showed a high-resolution time-of-ﬂight electrospray
ionization mass spectrometry (ESIMS) [MþH]þ ion peak at
m/z 636.2679, indicating the molecular formula of C27H37N7O11
(þ 0.3 p.p.m.) requiring 13 of unsaturation (Supplementary
Fig. 8). The one-dimensional (1D; 1H, 13C) and two-dimensional
(2D; gHSQCAD, gHMBCAD and gCOSY) NMR data acquired in
CD3ODþD2O (4:1) indicated the peptidic nature of 1
(Supplementary Figs 9–13) by the presence of 8 methyl/methine
carbons, 10 methylene carbons and 9 carbonyls/quaternary car-
bons. Analysis of gCOSY, TOCSY and gHMBC cross peaks at dH
7.01, 7.48, 6.97 and 7.71 to dC 159.7 and 159.8 suggested the spin
system consisting of an ortho-substituted phenol group. In
addition, correlations observed through long-range 1H–13C
between dH 4.69 (H-20a) and dC 168.6 (C-21) as well as 1H–1H
between dH 5.11 (H-19) and 4.61 (H-20b) interactions indicated
the moiety to be a N-terminal 2-phenyl-oxazoline group. Further
analysis of the gCOSY and TOCSY spectra indicated at least four
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more spin systems consisting of a serine (Ser), two modiﬁed
ornithines (Orns) and a modiﬁed alanine (Ala) (Supplementary
Figs 8–14). We deﬁned modiﬁed Orn as Nd-hydroxy-Nd-for-
mylornithine (N-OH-N-fOrn) based on the COSY relay observed
between dH 4.29 (H-10), 1.82 (H-11), 1.68 (H-12), 3.45 (H-13)
and a gHMBC correlation between H-13 and C-14 (dC 164.1).
Similarly, another Orn-like spin system potentially related to a
piperazic acid (Pip) based on long-range 1H–13C between dH
3.57, 3.63 (H-8)-dC 173.9 (C-9) and a short-range 1H–1H array
observed from H-5 to H-8 (Fig. 1). The C terminus of the peptide
was identiﬁed as b-alanine (b-Ala) based on COSY correlation
between H-3 (dH 3.47, 3.39) to H-2 (dH 2.39) and an HMBC
correlation from H-3 to C-1 (dC 174.1). All deduced moieties
completed the planar structure of 1 (Fig. 1; Supplementary
Table 1).
Cahuitamycin B (2) was isolated by RP-18 HPLC from the
same C18 fraction containing compound 1. The high-resolution
ESIMS (HRESIMS) [MþH]þ ion peak at m/z 654.2759
provided a molecular formula of C27H39N7O12 with only 12 of
unsaturation compared with 13 in 1 (Supplementary Fig. 15).
Moreover, the 1D NMR data although acquired in dimethyl-
sulphoxide (DMSO)-d6, showed high structural similarity to 1
with the existence of six carbonyls (between dC 164.8 and 171.1),
an aldehyde (dC 161.6, dH 8.21) and a phenyl group functionality
(between dC 116.7–156.9 and dH 6.81–7.91) fulﬁlling 11 out of 12
degrees of unsaturation. Analysis of the 2D NMR data for 2
suggested a similar carbon backbone as 1 except the gCOSY and
HMBC cross peaks at dC 55.4, dH 4.56 (C-16)—dC 61.5, dH 3.58,
3.63 (C-17) and dC 55.2, dH 4.52 (C-19)—dC 61.7, dH 3.69, 3.73
(C-20) indicating two Ser groups, replacing the ring in 1,
respectively (Fig. 1; Supplementary Figs 16-20). Furthermore,
similar COSY and HMBC correlation as observed in 1 suggested
the presence of Pip, thus accounting for the 12th degree of
unsaturation to complete the structure of 2 (Supplementary
Table 1).
Cahuitamycin C (3) was also isolated as a white amorphous
solid from the same C18 fraction containing 1 and 2. The
HRESIMS [MþH]þ ion peak at m/z 650.2804 provided a
molecular formula of C28H39N7O11 with 13 degrees of unsatura-
tion (Supplementary Fig. 21). Extensive 1D and 2D NMR analysis
indicated that 3 shares structural similarity on much of the
carbon backbone compared with 2 (Supplementary Table 1). The
only observed difference was localized to the phenyl ring system
where an HMBC correlation from dH 2.51 (H-24) singlet to dC
123.1 (C-25) and 112.8 (C-22) suggested methylation of
the N-terminal 2-hydroxybenzoyl-oxazoline group at C-23
(dC 141.2). Furthermore, a change in 1H multiplicity at dH
6.73 (H-25) to a doublet conﬁrmed the planar structure of 3
(Fig. 1; Supplementary Figs 22–26).
Stereochemical studies for cahuitamycins A–C. Due to the
polypeptidic nature of the cahuitamycins, we pursued advanced
Marfey’s analysis21,22 to ascertain absolute stereochemistry.
Initially, only cahuitamycin B (2) was selected for acid
hydrolysis followed by 1-ﬂuoro-2,4-dinitrobenzene-5-alanine
amide (FDAA) derivatization. This was based on 2 appearing
to be the congener leading to production of cahuitamycins A and
C (1 and 3) following cyclization or vice versa (see further below).
A study was conducted to compare m/z 357.27, 382.32 and
400.34 channels from liquid chromatography/electrospray ioniza-
tion/mass spectrometry (LC-ESI-MS) chromatograms between
the L-FDAA and D, L-FDAA-derivatized Ser, Pip and N-OH-Orn
(a hydrolysed product of N-OH-N-fOrn) products of 1,
respectively. Analysis clearly revealed the absolute conﬁguration
of the moieties in the hydrolysate of 1 to be L-Ser, L-Ser, D-Pip and
D-N-OH-Orn, respectively (Fig. 1).
Furthermore, analysis of the Ser, Pip and N-OH-Orn
portions of 1 and 3 was conducted as described above
for 2, revealing the same stereochemistry. The absolute
conﬁguration of the oxazoline ring in 1 and 3 was extrapolated
to be D based on similar NMR chemical shifts compared with 2,
as well as the absence of an epimerization domain in the ﬁrst
module (CahA) of the cahuitamycin biosynthetic gene cluster
(see above, Fig. 2).
Afﬁnity of cahuitamycins towards iron. Cahuitamycins were
observed to have siderophore-like properties, and we therefore
conducted competition titrations with EDTA to identify
their relative iron-binding afﬁnities23. In this method, the
Fe–cahuitamycin complex was incubated with varying
concentrations of EDTA and assessed for Fe distribution using
ultraviolet–visible spectroscopy (Methods). The pFeIII for
cahuitamycins were calculated against the known stability
constants for EDTA (pFeIII¼ 23.42)24. Three individual
titrations were conducted for each natural product, and the
representative pFeIII values for cahuitamycins 1–3 were measured
to be 18.34±0.16, 20.42±0.09 and 17.52±0.12, respectively
(Supplementary Fig. 38). Importantly, the calculated pFeIII for
1–3 was signiﬁcantly lower than those previously reported for
hydroxamate siderophores under similar physiological condition
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Figure 1 | Structures of cahuitamycins A–C (1–3) with absolute
stereochemistry. Cahuitamycin A shows key HMBC and COSYcorrelations.
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(B25–37)25. This supports our hypothesis that cahuitamycins
possess siderophore properties, but their relatively low afﬁnity
may indicate it to be a secondary endogenous function.
Interestingly, the diminishing activity of 1 over an extended
bioassay time course and the observed inverse propor-
tionality between pFeIII of 1–3 against A. baumannii bioﬁlm
inhibition could be attributed to this iron chelation property
(see below).
Dissecting the cahuitamycin biosynthetic gene cluster. To mine
a candidate gene cluster for cahuitamycin biosynthesis, analysis of
the draft genome sequence of S. gandocaensis was performed
using antiSMASH26. As a result, a gene cluster was identiﬁed
(GeneBank accession code KU363800) as potentially responsible
for nonribosomal peptide scaffold biosynthesis, transport and
regulation of cahuitamycins A and B (1 and 2; Fig. 2a).
Cahuitamycin C (3) biosynthesis was initially expected to
involve a S-adenosyl-L-methionine-dependent C-methyltransferase
through post-assembly tailoring. However, the absence of genes
responsible for the formation of a methyl group at C-23 position
of 3 (Fig. 1) near cluster 1 led to the hypothesis that another
genetic locus encoding 6-methyl salicylate synthase (6-MSAS)
might be involved in its biosynthesis (Fig. 2). The architecture
and annotation of the bifurcated cahuitamycin (cah) gene cluster
is shown in Fig. 2 and Supplementary Table 4, respectively. The
cluster containing nonribosomal peptide synthetase (NRPS)-
encoding genes cahA–D, together with genes involved in chain
initiation (cahIJ), termination (cahG) and a transcriptional
regulator (cahR), is located in a region spanning B40 kb of
DNA. Each NRPS protein consists of the essential condensation
(C), adenylation (A) and thiolation (T) domains (Fig. 2b), and
has a non-colinear architecture.
CahA is proposed to catalyse oxazoline ring formation together
with a putative salicylate synthase CahI and salicylate-AMP ligase
CahJ (Fig. 2b). CahI is homologous to MbtI from Mycobacterium
tuberculosis and is predicted to convert chorismate to salicylate
(Fig. 2b)27. CahJ bears high similarity to a salicylate-AMP ligase
MxcE from Sorangium cellulosum So ce56 (ref. 28), which
suggests that it activates salicylate by adenylation (Fig. 2b). The
identity of amino acid building blocks selected and activated by
the Cah NRPS were analysed by examining the speciﬁcity-
conferring residues in each A domain (Supplementary Table 5)29.
The A domain in CahA is predicted to recognize L-Cys
(Supplementary Table 5), though only L-Ser is loaded according
to the structure of cahuitamycins (Fig. 1), which is also observed
in the amychelin biosynthetic system30. The heterocyclization
between Ser and the carbonyl group to form an oxazoline ring
scaffold can be attributed to the Cy domain in CahA, and the
resulting peptide product is then transferred to CahB for
synthesis of 1 and 3. Similar to formation of gobichelins, where
the oxazoline ring of gobichelin A is hydrolysed into a linear form
under non-acidic condition, 1 may convert to 2 with a free Ser
through hydrolysis of the oxazoline ring31. The in silico analysis
of A domains in CahB predicts activation of L-Ser and L-N-OH-
N-fOrn by CahB-A1 and CahB-A2, respectively (Supplementary
Table 5). Subsequent to the incorporation of L-Ser by CahB-A1,
a L-N-OH-N-fOrn moiety, which is synthesized from L-Orn
by a putative Orn hydroxylase (CahMO) and a putative
a
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N-formyltransferase (CahFT)32, is appended to the growing chain
(Supplementary Table 4). The L-N-OH-N-fOrn moiety linked to
the T2 domain of CahB undergoes epimerization by the
epimerase (E) domain33, which is consistent with the stereo-
chemistry of cahuitamycins (Fig. 1; Supplementary Figs 8–37).
Biosynthesis of cahuitamycins likely involves formation and
loading of the piperazic acid (Pip) building block into the growing
peptide chain. Although the relatively rare Pip moiety is found in
several biologically active secondary metabolites34–39, the precise
biosynthetic events for Pip elaboration have not been elucidated.
Recent precursor incorporation experiments have suggested that
generation of the Pip moiety in kutzneride occurs before
incorporation into the respective peptide chain35, similar to the
formation of a hydrazo linkage in valanimycin34. It is likely that
biosynthesis of the Pip moiety in cahuitamycin is initiated by N-
hydroxylation of the amino group of Orn by a putative CahMO.
The resulting L-N-OH-Orn residue attached to the T domain of
CahC would be converted to its corresponding D-stereoisomer
(D-N-OH-Orn) by the E domain within the same module
followed by nucleophilic attack of the amino group to close the
ring. Alternatively, since the A domain in the CahC is
homologous to L-glutamine (Gln)-activating A domains
(Supplementary Table 5), it is possible that Gln may be
incorporated as a branch point from primary metabolism into
the piperazate biosynthetic pathway (Fig. 2)40,41.
Further in silico analysis of the A domain in CahD
(Supplementary Table 5) predicted loading of b-Ala onto the T
domain consistent with the structure of cahuitamycins. Moreover,
it further afﬁrms that the presence of b-Ala residue is likely
formed from L-aspartate (L-Asp) by the cahF gene product42. The
CahD polypeptide contains neither C-terminal thioesterase nor a
reductase domain usually required for chain release in
nonribosomal peptide biosynthesis, and likely involves a speciﬁc
hydrolase for release of the fully assembled peptide chain from
the T domain of the last module CahD. We propose that
following ﬁnal extension by b-Ala, CahG (a/b hydrolase
superfamily) catalyses in trans release of the peptide chain
through hydrolysis of the T domain-bound thioester as described
previously in coelichelin biosynthesis43.
Moreover, CahE, an MbtH-like protein homologue, likely
contributes to the stimulation of A domains in the Cah NRPS44.
CahH, which belongs to the major facilitator superfamily, is
similar to EntS, an enterobactin efﬂux exporter of Escherichia coli.
Proteins encoded by CahT1 through CahT8 are putatively
required for iron uptake and translocation of cahuitamycin
across the cell membrane (Supplementary Table 4). Therefore,
these proteins might be involved in the export of cahuitamycins
from the cytoplasm into the medium. Open reading frame 1
(ORF1), ORF2 and ORF3 show sequence similarity to
oxidoreductase, acyltransferase and 6-aminohexanoate-oligomer
hydrolase, respectively, and their relationship to cahuitamycin
biosynthesis remains unclear (Supplementary Table 4).
Biosynthesis of cahuitamycin C. We next sought to conﬁrm the
function of the assigned biosynthetic cluster by deletion of cahI in
S. gandocaensis through insertion of the kanamycin resistance
gene (aph). Surprisingly, the DcahI S. gandocaensis strain
DHS334 (Methods; Supplementary Fig. 7; Supplementary
Table 7) gave exclusive production of 3, while the production
of 1 and 2 were completely abolished (Fig. 3d). The result indi-
cated a possible unlinked source involved in providing 6-
methylsalicylate starter unit. A BLAST analysis using bacterial 6-
MSASs including various putative candidates from other bacterial
secondary metabolite gene clusters45–49, led to the identiﬁcation
of a single iterative type I PKS gene encoding a 6-MSAS (genetic
locus 2; GeneBank accession code KU363801) located at least
B50 kb away from cluster 1 based on our S. gandocaensis draft
genome-sequencing data (Fig. 2a). This ﬁnding led us to propose
that the 6-methylsalicylate starter unit is likely derived from the
6-MSAS identiﬁed from bioinformatics mining, which is
subsequently adenylated by CahJ and loaded onto the T1
domain of CahA for production of 3 (Fig. 2). As in other
bacterial PKSs in its class, the putative cahuitamycin 6-MSAS
(genetic locus 2; cah MSAS) possesses keto synthase,
acyltransferase, dehydratase, ketoreductase and acyl carrier
protein domains on a single protein (Supplementary Table 4).
The hypothesis was further substantiated by the dosing effect
observed by introducing exogenous 6-methylsalicylic acid into
cultures of the DcahI S. gandocaensis strain. The feeding study
provided increased production of 3, while no changes were
observed in production of 1 and 2 (Supplementary Fig. 39). This
result, together with the lack of other potential sources of 6-
methylsalicyclate, or a candidate methyltransferase encoded
within the S. gandocaensis genome appears to rule out the
possibility of any posttranslational modiﬁcation of 1 to produce 3.
Furthermore, production of 1 and 2 was restored by external
supplementation of salicylic acid to the DcahI growth medium
(Fig. 3e), representing chemical complementation and
conﬁrmation of its role in the production of cahuitamycins.
These studies substantiated that biosynthesis of 3 is independent
of cahI-mediated salicylic acid biosynthesis, and more
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Figure 3 | Chemical complementation of the cahI deletion mutant of
S. gandocaensis. LC-ESI-MS chromatograms of 1–3 obtained from culture of
DHS287 (a–c) the cahI deletion mutant DHS334 (d) supplemented with
100 mM of salicylic acid (e).
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importantly cahuitamycin C (3) appears to be derived from a
convergent biosynthetic pathway (Fig. 2). Secondary metabolites
assembled from unlinked gene clusters have been reported in
previous studies32,50,51, but to the best of our knowledge this is
the ﬁrst example of a starter unit pathway that is genetically
unlinked to a corresponding bacterial NRPS. The observation
provides an intriguing example where S. gandocaensis may be
diversifying its biosynthetic machinery to produce a more potent/
toxic metabolite for enhanced competitiveness in its natural
habitat.
Mutasynthetic generation of cahuitamycin analogues. The
biosynthetic process for generating 3 revealed the possible
tolerance of CahJ towards structurally related salicylic acid sub-
strates, and a promising avenue for producing new cahuitamycin
analogues by mutasynthesis52. In this approach, we provided
the DHS334 DcahI strain with a series of substituted benzoic
acid substrates (Supplementary Fig. 40), and sequentially
assessed their incorporation to make new analogues (Fig. 4).
Of the series of unnatural starter units tested, feeding of
methyl-hydroxybenzoic acid substrates showed some level of
incorporation. However, only assimilation of 5-methylsalicylic
acid into the DcahI pathway provided isolable quantities of the
new analogue, cahuitamycin D (4; Fig. 4a; Supplementary
Fig. 40).
Cahuitamycin D (4) was isolated by reverse-phase HPLC (RP-
HPLC) from crude extract of DcahI mutant. The HRESIMS
[MþH]þ ion peak at m/z 650.2706 provided similar molecular
formula as of 3, C28H39N7O11. Extensive 1D and 2D NMR
data were acquired for 4, which indicated the expected structural
similarity with 3, as per the mutasynthesis hypothesis
(Fig. 4a; Supplementary Table 2). The structure showed a similar
carbon backbone with a clear difference at the phenyl ring system
compared with 3. Cahuitamycin D (4) shows the presence
of a singlet at dH 7.78 (H-23) with HMBC correlation to
dc 20.3 (C-25) and dc 129.4 (C-24), suggesting methylation
at C-24 consistent with the hypothesized incorporation of
5-methylsalicylic acid to the mutant strain DHS334 of
S. gandocaensis.
Furthermore, during isolation of 4, we observed another HPLC
peak eluting with this natural product (Fig. 4b). Interestingly, the
HRESIMS [MþH]þ ion peak at m/z 668.2830 suggested the
same backbone with likely additional hydration. The new
molecule cahuitamycin E (5) was shown by 1D and 2D NMR
analysis to share structural similarity on much of the carbon
backbone compared with 4 (Supplementary Table 2). The only
plausible difference could be traced to the C-5 position where Pip
moiety in 4 was substituted with L-N-OH-Orn in 5, suggested
based on the COSY relay observed from dH 4.33 (H-5) to dH 3.45
(H-8) along with absence of any signiﬁcant HMBC correlation
from H-8 to C-9 (dC 172.2) (Fig. 4b). The observation was
compelling as it indicates that either the cyclization to form Pip
moiety is occurring after the insertion of L-N-OH-Orn in 5 or,
alternatively, the domain is capable of accepting both moieties
separately. In addition, the study also indicated that L-glutamine
might not be a substrate for the CahC A domain during
biosynthesis of cahuitamycins.
The absolute stereochemical conﬁguration of the cahuitamy-
cins D and E (4 and 5; Fig. 4) was extrapolated to be the same as
cahuitamycins A–C (1–3) based on very similar chemical shifts
observed for all nuclei obtained through detailed 1D and 2D
NMR analysis (Supplementary Table 2).
Biological activity associated with cahuitamycins A–E. Cahui-
tamycins A–C (1–3) were next tested for their ability to inhibit
bioﬁlm formation of A. baumannii using a high-resolution optical
secondary assay system. The primary high-throughput static
bioﬁlm assay leading to identiﬁcation of 1–3 was conducted using
crystal violet staining followed by optical density measurements
(Fig. 5a,b). The result from this assay showed that 1 was able to
inhibit, while 2 had no effects on bacterial growth or bioﬁlm
formation (Fig. 5a,b). Interestingly, 3 possessed the highest
potency with half-maximal inhibitory concentration (IC50)
values of 14.5 mM while having a limited effect on growth of
A. baumannii. In addition, a confocal laser scanning microscope
imaging analysis of bioﬁlm formation and biomass was
performed (Methods). In this assay, the bioﬁlm was developed on
a 12-well glass plate with solvent (no compound) as a negative
N
H
N
O
NHO
N
H O
HOO
N
O
OH
OH
O NH
O OH
HN
N
H
H
N
O
NHO
N
H O
HOO
N
O
OH
OH
O NH
O OH
HN OH
Cahuitamycin D (4)
Cahuitamycin E (5)
1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5
Counts (%) versus acquisition time (min)
Counts (%) versus acquisition time (min)
×102
×102 + EIC(650 2385) Scan Cahl_5M SA
+ EIC(668 2830) Scan Cahl_5M SA
a
b
Figure 4 | Mutasynthetic generation of cahuitamycins D and E (4 and 5) and their complete structures. LC-ESI-MS chromatograms of 4 (a) and 5 (b)
obtained from a culture of the cahI deletion mutant DHS334 supplemented with 100 mM of 5-methylsalicylic acid.
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control and only 240 nM of 1 and 3 as treated. After staining with
ﬂuorescent dye SYTO9 and propidium iodide, the bioﬁlm
structure was observed (Fig. 5c). The reconstructed three-
dimensional (3D) bioﬁlm images obtained showed a much
thinner bioﬁlm and also signiﬁcantly less total biomass for the
glass plates treated with 1 and 3 compared with control (Fig. 5c).
Furthermore, the glass plate treated with 3 showed a much lower
level of total biomass compared with 1 at the same concentration
(0.10mm3 versus 0.18 mm3), which conﬁrmed 3 as the
more potent bioﬁlm inhibitor (Fig. 5c).This ﬁnding indicates that
cahuitamycins prevent bioﬁlm formation through a speciﬁc,
yet currently undeﬁned biochemical target with negligible impact
on cell growth (Fig. 5a,b). Furthermore, cahuitamycin C (3)
was tested against the growth of A. baumannii separately
(Supplementary Fig. 41), and revealed an IC50 value ofZ1.0mM
(Supplementary Fig. 42). In addition, when 1 (the most abundant
molecule) was tested in iron-complexed form (owing to its
moderate iron chelation afﬁnity), it showed minimal impact on
both growth and bioﬁlm formation of the pathogen (Fig. 5a,b).
To probe iron chelation as a possible mode of action for the
cahuitamycins, a known siderophore desferrioxamine was
used as control, which showed no activity, suggesting that iron
chelation (or depletion) may not be the basis for cahuitamycin
activity (Supplementary Figs 38 and 44). However, loss of inhi-
bition of bioﬁlm formation over time could be attributed to the
metal-complexed cahuitamycins (Supplementary Figs 38 and 44),
as the test media is replete with iron and 1 in complex with
FeIII has not displayed comparable inhibitory activity (Fig. 5a).
This observation is consistent with previous studies, which
have reported that clinical isolates of A. baumannii are able to
grow in the presence of high concentrations of different iron
chelators due to its ability to express a high-afﬁnity extracellular
siderophore, acinetobactin53,54. In addition, the structural
differences between cahuitamycins with previously reported
amychelin30, results in a signiﬁcant change in iron afﬁnities,
which can be further explored for bioﬁlm inhibitory properties in
future studies.
Next, we sought to probe the speciﬁc stage and extent of
inhibition during bioﬁlm formation employing a secondary ﬂow
cell assay (Supplementary Fig. 44; Methods). This analysis
revealed almost the same number of cells initially attached to
the surface before starting treatment. After 6 h of inhibitor
supplementation, the ﬂow cells treated with 1 showed only a few
microcolonies of the pathogen, while the control (no treatment)
and desferrioxamine showed formation of a robust bioﬁlm. After
24 h of supplementation, the control and desferrioxamine
bioﬁlm became thicker with the ﬂow cells exposed to 1 showing
larger microcolonies and initiation of bioﬁlm formation by
A. baumannii.
As described above, the mutasynthetic study on S. gandocaensis
strain DHS334 led to the isolation of two additional analogues
cahuitamycins D–E (4–5). The new molecules were also subjected
to static bioﬁlm assays and the result demonstrated that 4
displayed almost twice the potency (IC50¼ 8.4 mM) compared
with 3, which we earlier considered to be the most active
molecule (Fig. 6; Supplementary Figs 41–43). Furthermore,
cahuitamycin E (5) also displayed signiﬁcant activity with an
IC50 of 10.5 mM (Fig. 6; Supplementary Figs 41–43). In addition,
compounds 3 and 4 were also tested for disruption of established
A. baumannii bioﬁlm revealing low activity with an IC50 of 692
and 535 mM, respectively (Supplementary Fig. 45; Methods),
establishing their better efﬁcacy as bioﬁlm formation inhibitors.
Although prophylactic antibiotic administration preceding sur-
gery is routinely successful in reducing infection rates, it has little
or no protective effects in surgical procedures involving implants
or prostheses55. Therefore, catheters and implants coated with
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Figure 5 | Biological activity of cahuitamycins A–C (1–3). (a) Growth of A. baumannii ATCC 17978 and (b) inhibition of bioﬁlm in the presence of
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bioﬁlm-inhibiting antimicrobial agents are urgently needed as an
effective, precision therapeutic option. Our current data indicate
that a key pharmacophore of the cahuitamycins is likely
the 2-hydroxybenzoyl-oxazoline group where relatively minor
modiﬁcations can result in an increase (as in case of 3–5) or
decrease (as for 2) of anti-bioﬁlm activity, with the potential for
further structure activity relationship studies using synthetic
chemistry or Cah pathway engineering.
The application of the streptomycin resistance-mediated
screening of the Streptomyces strain identiﬁed from HTS against
A. baumannii has yielded a novel structural class of bioﬁlm
inhibitors derived from a marine microbial NPE library.
Cahuitamycins A–E (1–5) inhibit the ability of A. baumannii
to generate a bioﬁlm, which is involved in the emergence
of a widespread antibiotic resistance phenotype6,56. The
cahuitamycins are most active in apo form, with chelation of
FeIII over time resulting in attenuated biological activity. The
cahuitamycins along with allied chemical entities with distinct
biological activity provides a primary foundation for future
medicinal chemistry and synthetic exploration towards the
development of an efﬁcacious drug to prevent or limit bioﬁlm
formation.
We have also demonstrated that production of cahuitamycins
A–C is speciﬁed by a convergent pathway speciﬁed by the cah
biosynthetic gene cluster comprised of two unlinked genetic loci.
The inherently ﬂexible starter unit adenylating enzyme CahJ was
exploited to produce two additional analogues in the engineered
DcahI strain DHS334. The new cahuitamycin D analogue displays
twofold-enhanced bioﬁlm inhibitory activity compared with the
cahuitamycin C natural product. These results establish a unique
opportunity for developing and discovering new antibiotics from
genetically engineered strains bearing inherent ﬂexibility in
pathway initiation processes. More importantly, given the
simultaneous decline in antibiotic drug discovery and increased
incidence of multidrug resistant bacteria, the cahuitamycins may
represent a propitious starting point for discovery and develop-
ment of new therapeutics against dangerous human pathogens
involving bioﬁlm formation.
Methods
General experimental procedures. Optical rotation measurements were obtained
on a Perkin-Elmer 241 Polarimeter calibrated using a Rudolph Quartz Control
Plate Calibration Standard at sodium D line (at þ 11.502). Ultraviolet spectra
were obtained on a UV-visible Molecular Devices SpectraMax M5 spectro-
photometer using 1-ml cuvettes with 1.0 cm path lengths at room temperature in
solvent methanol (MeOH). Spectrophotometric assays were performed on Mole-
cular Devices SpectraMax M5 384 variable wavelength spectrometer. All NMR
spectra were acquired on a Varian INOVA 600MHz and a Varian INOVA
700MHz spectrometer at the NMR Facility, Department of Chemistry, University
of Michigan. HRESIMS spectra were measured at the University of Michigan core
facility in the Department of Chemistry using an Agilent 6520 Q-TOF mass
spectrometer equipped with an Agilent 1290 HPLC system. RP-HPLC was
performed using Econosil C18 10 mm 22 250-mm column and Agilent ZORBAX
RX-C8 5 mm 9.4 250-mm column and a solvent system of MeCN and H2O. The
LC-MS analysis of HPLC fractions was performed on a Shimadzu 2010 EV APCI
spectrometer.
Biological material. S. gandocaensis (Strain # 12620-H2) was isolated from marine
sediments collected from Punta Mona Island (protected area:  82o 370 1.500 0 , 09o
370 56.20 0 RVS Gandoca Manzanillo with collection permit R-CM-INBio-30-2007),
Costa Rica, on 5 June 2007. The procedure for the isolation of actinomycetes from
these samples was previously described by Magarvey et al.16 Maintenance and
propagation of cultures were performed using standard media and protocols where
500mg of wet sediment was diluted in 10ml of sterile water and vortexed for
10min. Then, 1ml of this suspension was applied directly to the top of the
discontinuous sucrose gradient and centrifuged for 30min at 300g. A volume of
500 ml of the 20, 30 and 40% layers was then plated to HVA agar supplemented
with 10mgml 1 chlortetracycline, 25mgml 1 cyclohexamide and 25mgml 1 of
nalidixic acid. The plates were then incubated at 28 C for 1 month. The colony was
picked off the plate and streaked onto ISP2 agar until pure. Seed cultures were
grown in 17-ml dual-position cap tubes containing 2ml of ISP2 and grown for 4
days on a rotary shaker at 200 r.p.m. The seed culture was then poured into
a 250-ml bafﬂed ﬂask containing 100ml of ISP2 and grown for 18 days on a rotary
shaker at 200 r.p.m. The culture was centrifuged at 4,000 r.p.m. for 10min to
remove the cells, and 2 g of XAD16 resin (Sigma-Aldrich, St Louis, Mo) contained
within a polypropylene mesh bag was added to the broth and incubated overnight
on the rotary shaker. The resin bag was removed and placed into 10ml of MeOH,
followed by 10ml of acetone and 10ml of ethyl acetate (EtOAc). Each of the three
fractions was dried in vacuo and reconstituted to a ﬁnal concentration of
15mgml 1 in DMSO.
Culture maintenance and fermentation. Seed cultures of 100ml (5 ) of ISP2
media (1% malt extract, 0.4% yeast extract, 0.4% dextrose and 3% NaCl) were
inoculated with a loop-full of vegetative cells from an oatmeal plate (6% oat meal,
1.25% agar and 3% NaCl) culture of S. gandacoensis and incubated with shaking
(200 r.p.m.) at 28 C for 5 days. A 25ml portion of the seed cultures were trans-
ferred to a 2.8-l Fernbach ﬂask containing 1.5 l of the ISP2 medium, and the 39 l
fermentation was carried out on a rotary shaker (200 r.p.m.) at 28 C for 18 days.
After 14–18 days of growth, the cultures were collected by centrifugation. The
resulting cell-free broth was subjected to solid phase extraction using 15 g of
Amberlite XAD-16. The resin was then separated by ﬁltration and subjected to
organic extraction using MeOH:EtOAc (1:1).
Natural product extract library. The NPE library at the University of Michigan
Center for Chemical Genomics contained B20,000 extracts. Each extract in the
library is derived from marine samples collected from all over the world, including
Costa Rica, Panama and Papua New Guinea. Some of these samples are from
isolated microbes (n¼ 19,055), while others were derived from ﬁeld-collected
biomass samples (‘macrosamples,’ n¼ 800). Previous work describes in detail how
these extracts are prepared for the library16.
PCR ampliﬁcation, cloning and sequencing of 16S rDNA. Genomic DNA
of S. gandocaensis was isolated using the Wizard Genomic DNA Puriﬁcation Kit
according to the manufacturer’s instruction. The 16S ribosomal DNA (16S rDNA)
gene was ampliﬁed by PCR with the universal primers FC27 and RC1492
(Supplementary Table 6)57 using the genomic DNA as a template. The PCR
fragments were cloned into pGEM-T Easy vector (Promega) and the resulting
plasmid containing 16S rDNA of S. gandocaensis was sequenced using T7 and
SP6 primers.
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Phylogenetic analysis of 16S rDNA of S. gandocaensis. Phylogenetic analyses
were conducted using GENEIOUS R6 that is available from http://www.
geneious.com/ (ref. 58). The evolutionary history was inferred using the
Neighbour-Joining method. The bootstrap consensus tree inferred from
500 replicates was taken to represent the evolutionary history of the taxa
analysed (Supplementary Fig. 6).
Generation of ribosome-engineered mutants of S. gandocaensis. Spores
(108–109) of wild-type S. gandocaensis were spread on R2YE agar containing
various concentrations of streptomycin, followed by 15 days incubation at 28 C to
allow the development of streptomycin-resistant colonies. Eighty resistant colonies
(Supplementary Fig. 4) were obtained from the plate containing a high level (10, 50
and 100 mgml 1) of streptomycin and grew in ISP2 media with streptomycin for
14 days at 28 C. This step was repeated four times to obtain spontaneous strep-
tomycin-resistant mutants. The ability of selected mutants to produce cahuita-
mycin was tested by LC-MS using Agilent extend C18 5 mm 2.1 150-mm column
on gradient condition 30–85% acetonitrile (w/0.1% formic acid) in H2O (w/0.1%
formic acid) over 15min with additional 5min of equilibration time.
Ampliﬁcation and sequencing of rpsL. Nine strains, including the parent strain
and eight high-yielding recombinants, were selected to determine mutations
in the rpsL gene in this study. The rpsL gene was ampliﬁed by PCR with primers
SR185 and SR186 (Supplementary Table 6), using genomic DNA as a template and
cloned into pGEM-T easy vector (Promega) and sequenced. Mutations in the
wild-type rpsL gene were determined by DNA sequencing59 (Supplementary Fig. 5;
Supplementary Table 3).
Isolation and puriﬁcation of cahuitamycins. The organic extracts obtained from
the engineered strains were concentrated under vacuum to afford the crude extracts
(B350mg) obtained from 100-ml culture. The crude extract was assayed in the
developed in vitro crystal violet at 10 and 1.0 p.p.m. The bioactive extract was then
further puriﬁed by RP-HPLC on a gradient of 10–75% ACN and was followed by
ultraviolet–visible photodiode array detection at 215 nm to yield semi-pure com-
pounds 1 (6.7mg), 2 (2.4mg) and 3 (2.9mg). Compounds were again subjected to
repuriﬁcation over RP-HPLC on isocratic condition of 35% MeOH (0.1% FA)
using C-8 column to get compounds 1 (5.1mg), 2 (1.1mg) and 3 (1.6mg).
Cahuitamycin A (1). Bone white, amorphous powder; ultraviolet (ACN:H2O)
lmax 203, 245, 249, 255 and 304 nm; 1H and 13C NMR, see Supplementary Table 1;
HRESIMS m/z 636.2679 [MþH]þ (calculated for C27H38N7O11, 636.2629).
Cahuitamycin B (2). Bone white, amorphous powder; ultraviolet (ACN:H2O)
lmax 203, 240, 249, 255 and 304 nm; 1H and 13C NMR, see Supplementary Table 1;
HRESIMS m/z 654.2759 [MþH]þ (calculated for C28H40N7O11, 654.2735).
Cahuitamycin C (3). Bone white, amorphous powder; ultraviolet (ACN:H2O)
lmax 200, 245, 249, 255 and 304 nm; 1H and 13C NMR, see Supplementary Table 1;
HRESIMS m/z 650.2804 [MþH]þ (calculated for C27H38N7O11, 650.2786).
Generation of cahI deletion mutant. The cahI gene was inactivated by an
insertional inactivation via double-crossover homologous recombination
(Supplementary Fig. 7A). A knock-out plasmid pSRP50 based on pKC1139
(ref. 60) was constructed by amplifying kanamycin resistance gene as a selection
marker from plasmid pYJ276 (ref. 61), and left-and-right-ﬂanking regions of the
cahI gene using the genomic DNA of S. gandocaensis as a template. The primer
pairs SR144-SR145, SR146-SR147 and SR148-SR149 (Supplementary Table 6) were
designed for the ampliﬁcation of left-and-right-ﬂaking fragments of cahI gene, and
selection marker, respectively. DNA assembly was performed using Gibson
assembly62 master mix (New England Biolabs) according to the manufacturer’s
instructions. The plasmid pSRP50 was passaged through methylation-deﬁcient
E. coli ET12567 and then introduced into the S. gandocaensis by protoplasts-based
transformation63. The target region of cahI gene was then disrupted by an
insertional inactivation via double-crossover homologous recombination. The
desired mutant DcahI was selected by its kanamycin-resistant and apramycin-
sensitive phenotype (Supplementary Fig. 7b) and veriﬁed by PCR (Supplementary
Fig. 7c) using the primer pair SR233–SR234 (Supplementary Table 6). The
resulting cahI deletion mutant of S. gandocaensis was designated as DHS334.
Chemical complementation of mutant DHS334 and mutasynthesis. Mutant
strain of DHS334 was ﬁrst precultured in 3ml R2YE liquid medium for 15 days at
28 C and then 3ml of the seed culture was used to inoculate 100ml of the same
medium, followed by cultivation for 15 days at 28 C. Salicylic acid and a series of
substituted benzoic acid substrates, 2-hydroxybenzoic acid, 2,3-dihydroxybenzoic
acid, 2,4-dihydroxybenzoic acid, 2-ﬂuorobenzoic acid, 2-hydoxy-5-methylbenzoic
acid (5-methylsalicylic acid) and 2-hydoxy-6-methylbenzoic acid (6-methylsalicylic
acid) were added every alternate day to separate 100-ml cultures of DHS334 at a
ﬁnal concentration of 500mM for 15 days. The products were ﬁrst extracted using
Amberlite XAD-16. The resin was separated and subjected to organic extraction
using MeOH:EtOAc (1:1) for LC-MS analysis as described above.
The substrate-fed crude extract was then further puriﬁed by RP-HPLC on a
gradient of 10–75% ACN and was followed by ultraviolet–visible photodiode array
detection at 215 nm to yield semi-pure compounds 4 (2.4mg) and 5 (2.6mg).
Compounds were again subjected to repuriﬁcation over RP-HPLC on isocratic
condition of 35% MeOH (0.1% FA) using C-8 column to get compounds 4 (1.1mg)
and 5 (1.3mg).
Cahuitamycin D (4). Amorphous powder; ultraviolet (ACN:H2O) lmax 203,
240, 249, 255 and 304 nm; 1H and 13C NMR, see Supplementary Table 2;
HRESIMS m/z 650.2706 [MþH]þ (calculated for C28H40N7O11, 650.2786).
Cahuitamycin E (5). Amorphous powder; ultraviolet (ACN:H2O) lmax 200, 245,
249, 255 and 304 nm; 1H and 13C NMR, see Supplementary Table 2; HRESIMS m/z
668.2830 [MþH]þ (calculated for C28H42N7O12, 668.2891).
Determination of pFeIII for cahuitamycins A–C. Determination of pFeIII for
cahuitamycins was carried out as reported by Abergel et al. essentially without
modiﬁcations64. Brieﬂy, puriﬁed Fe-cahuitamycins, prepared as described above, was
dissolved in HEPES buffer (10mM HEPES and 0.1M KCl, pH 7.4) and ﬁve different
concentration ranges of ETDA were added from EDTA stock solutions also prepared
in HEPES buffer. Each reaction consisted of a total volume of 0.25ml, a ﬁnal
concentration of 0.1mM Fe-cahuitamycins and a range of 5–8,000-fold EDTA
(relative to Fe-cahuitamycins) in HEPES buffer. The reaction was allowed to
equilibrate at room temperature for at least 24 h, and ultraviolet–visible spectra were
subsequently recorded. The composite spectra contain contributions from both Fe-
EDTA and Fe-cahuitamycins. The e of both species as a function of l were
determined in HEPES buffer (see Supplementary Fig. 38 for Fe-cahuitamycins) and
used to deconvolute the spectra. The contribution of Fe-cahuitamycins was subtracted
from the composite spectra using the 435nm absorption band, and the e of both Fe-
cahuitamycins and Fe-EDTA were used to quantify the proportion of each species in
solution. Concentrations of apo-EDTA and apo-cahuitamycins were calculated by
subtracting [Fe-EDTA] (or [Fe-cahuitamycins]) from total initial EDTA (or Fe-
cahuitamycins). The log [EDTA]/[cahuitamycins] was plotted against log [Fe-EDTA]/
[Fe-cahuitamycins] and the data were ﬁt to equation (1), which has been derived by
Abergel et al.64. All the data sets are shown in Supplementary Fig. 38, yielding a pFeIII
as reported in original article.
log Fe-EDTA½ = Fe-cahuitamycin½ ð Þ ¼ log EDTA½ = cahuitamycin½ ð ÞþDpFeIII
ð1Þ
Assay development and high-throughput screening assay. A static bioﬁlm
assay was developed from a previously reported method19. The bioﬁlm assay
measures the adhesion of bacteria to the surface of polystyrene 384-well microtiter
plates. Adherent cells are detected by staining with crystal violet and subsequent
washing to remove nonadherent planktonic cells. Inhibitors of bioﬁlm formation
prevent the bacteria from adhering to the surface of the microtiter plate and reduce
the amount of crystal violet retained after washing. Assay quantiﬁcation was
performed by OD600 absorbance measurement of the crystal-violet-stained bioﬁlm.
The assay was optimized for plate surface treatment, time, temperature, media,
media concentration, crystal violet concentration, wash method, inhibitor
sensitivity and culture inoculum preparation.
The A. baumannii test strain (ATCC 17978) was maintained as a frozen stock at
 80 C in 20% glycerol. A volume of 5ml of Mueller Hinton II cation adjusted
media (Becton Dickinson, catalogue no. 212322) was inoculated and grown at
37 C, 180 r.p.m. shaking for 4–6 h. The culture was then diluted 1:50 and
incubated an additional 2 h. The resulting cells were washed four times by
centrifugation and resuspension of the pellet in media was performed to remove
any metabolites or cell signalling factors. The assay inoculum was prepared by
diluting the cells to 0.008 OD600 in 10% Mueller Hinton II cation adjusted media
(diluted in 18Ohm deionized water). The assay plates (Corning, catalogue no.
3,680; 384-well non-treated polystyrene) were prepared by dispensing 20 ml of 10%
Mueller Hinton II cation adjusted media into columns 1–22 using a Multidrop
Combi dispenser (Thermo Fisher). The NPE samples were added as 0.2 ml of
15mgml 1 stocks in DMSO using a Biomek FX high-density pintool (Beckman
Coulter). Column 1 and 2 contained DMSO without NPEs and served as the
negative control. The positive control was added to column 23 and 24 as 20 ml of
40 mM Baicalein (Sigma-Aldrich, catalogue no. 11712). The bacterial cells were
added to the entire plate in 20 ml of the prepared inoculum using a Multidrop
Combi dispenser (Thermo Fisher). The resulting assay contained 40 ml of 10%
Mueller Hinton II cation adjusted media with 0.004 OD600 bacterial cells, 0.5%
DMSO and 75mgml 1 NPE. The assay plates were incubated at 30 C for 20 h,
stationary, in a humidiﬁed incubator. The bioﬁlm was stained by adding 10 ml of
ﬁltered 1% crystal violet and incubating for 30min at room temperature. Excess
crystal violet and nonadherent planktonic cells were removed by washing three
times with 150 ml of PBS using an ELX405 plate washer (Bio-tek). The wash
program used a low velocity dispense rate and an aspiration height of 3.8mm;
B10 ml of PBS remained in the well after washing. The Crystal-Violet-stained
bioﬁlm was solubilized by the addition of 50 ml of 100% ethanol and allowed to
develop overnight. Quantiﬁcation was performed by measuring the OD600
absorbance using a Pherastar plate reader (BMG).
3D imaging of bioﬁlm development. For visualizing bacterial bioﬁlm formation,
the same method as described previously was used for bioﬁlm formation but in
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a glass-bottom 96-well plate (12–556–38, Fisher Scientiﬁc International Inc.,
Franklin, MA)65. After 20 h of incubation at 30 C, the supernatant was removed,
and the well surface was rinsed brieﬂy with 1 PBS buffer three times. PBS buffer
(100 ml) containing 1 mM of SYTO 9 and 10mM of propidium iodide was added
into the well. The plate was incubated for 15min in dark. Fluorescent images were
acquired with an Olympus Fluoview FV1000 confocal microscope (Olympus,
Markham, Ontario) with Melles Griot Laser supply and detectors and ﬁlter sets for
monitoring SYTO 9 and propidium iodide ﬂuorescence. Images were obtained
using an oil immersion  60 objective lens. 3D images were reconstructed using
the Amira software package (Amira, San Diego, CA) from a stack of sectional
images of bioﬁlm samples. Bioﬁlm biomass and per cent coverage were calculated
based on those images using software COMSTAT65.
Micrograph of bioﬁlm in ﬂow cells. Bioﬁlms were formed by A. baumannii
ATCC 17978 in ﬂow chambers at room temperature. Images were taken at 1, 6 and
24 h (using a  60 lens) after inoculation. A ﬂow cell bioﬁlm was achieved by using
a ﬂow cell chamber (ACCFL0001, Life Science Incorporated, Greensboro, NC).
Brieﬂy, overnight cultures of A. baumannii ATCC 17978 grown in MHII broth at
37 C were diluted 100-fold with fresh MHII broth. A volume of 1ml of dilution
was injected into a ﬂow cell chamber and allowed to settle 1 h for attachment of
bacteria, followed by initiation media ﬂow at a ﬂow rate of 4ml 1 h 1. Flow
media was 10% MHII broth (control), 10% MHII broth with 7.5 mgml 1 of
desferoxamine or 10% MHII broth with 7.5 mg 1ml of cahuitamycin A.
Micrographs of the bioﬁlm were acquired at 1, 6 and 24 h after the start of ﬂow
media using an Olympus IX70 microscope with a  60 lens. Flow was still running
while acquiring the micrograph.
Minimum inhibitory concentration test. Cultures of A. baumannii ATCC 17978
grown overnight were diluted into fresh 10% Mueller Hinton II broth to get 105
colony-forming unit per ml by determining optical density at OD600. A volume of
100ml of diluted cultures were incubated in individual wells of 96-well plate con-
taining 1% of DMSO and various concentrations of cahuitamycins C (3) and D (4).
The plate was incubated at 30 C with shaking at 150 r.p.m. The optical density of
each well was monitored every 1 up to 24 h using a microtiter plate reader (Synergy
HT, Bio-Tek, Winooski, VT). The number of viable bacterial cells was determined
by counting colony-forming unit.
Bioﬁlm dispersal assay. Bioﬁlm dispersal assay was performed as previously
reported66. Brieﬂy, A. baumannii ATCC 17978 bioﬁlm was developed as described
in minimum inhibitory concentration test. After 16 h incubation at 30 C, the
suspension in each well was removed by pipetting gently. A volume of 100 ml of
1 PBS buffer containing cahuitamycins C (3) and D (4) at various
concentrations was placed into each well. The plate was incubated at 30 C for 12 h
to allow cahuitamycins to disassemble pre-formed bioﬁlms. Then, the suspension
was removed by pipetting. The remaining attached bioﬁlm was quantiﬁed by
crystal violet assay.
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